TMDX vs. ITGR, LIVN, CNMD, SLNO, INMD, MASI, ALPN, SEM, IMVT, and PRGO
Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Integer (ITGR), LivaNova (LIVN), CONMED (CNMD), Soleno Therapeutics (SLNO), InMode (INMD), Masimo (MASI), Alpine Immune Sciences (ALPN), Select Medical (SEM), Immunovant (IMVT), and Perrigo (PRGO). These companies are all part of the "medical" sector.
Integer (NYSE:ITGR) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
99.3% of Integer shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 2.0% of Integer shares are owned by insiders. Comparatively, 7.0% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Integer received 289 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 63.45% of users gave Integer an outperform vote while only 54.78% of users gave TransMedics Group an outperform vote.
In the previous week, TransMedics Group had 1 more articles in the media than Integer. MarketBeat recorded 20 mentions for TransMedics Group and 19 mentions for Integer. Integer's average media sentiment score of 0.53 beat TransMedics Group's score of 0.51 indicating that TransMedics Group is being referred to more favorably in the news media.
Integer has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500.
Integer currently has a consensus price target of $127.00, indicating a potential upside of 12.29%. TransMedics Group has a consensus price target of $119.00, indicating a potential downside of 9.00%. Given TransMedics Group's higher probable upside, research analysts plainly believe Integer is more favorable than TransMedics Group.
Integer has a net margin of 6.01% compared to Integer's net margin of -3.43%. TransMedics Group's return on equity of 11.25% beat Integer's return on equity.
Integer has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
Summary
Integer beats TransMedics Group on 10 of the 18 factors compared between the two stocks.
Get TransMedics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TransMedics Group Competitors List
Related Companies and Tools
